GOALS AND BACKGROUND: AdMeTech Foundation’s Annual Global Summit and Brain Trust on Precision Diagnosis and Treatment of Prostate Cancer (Annual Global Prostate Summit, or AGPS) was established in September 2016. This educational event brought together – for the first time – the key international opinion leaders of every clinical subspecialty involved in patient care to bridge the gap between and integrate in-vivo imaging, in-vitro diagnostics (liquid and tissue biomarkers), biopsy and related technique, drug development and treatment.
This event has become seminal in shaping the state of the art and future vision for precision care by:
1) Educating the key healthcare stakeholders.
2) Creating and supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and
3) Expediting clinical adoption of promising novel diagnostics and therapeutics.
Our public Summit has been integrated with a private Brain Trust and recognized as one of the most influential educational and strategic efforts in prostate cancer for stimulating development and implementation of a comprehensive, multimodality approach to diagnostic patient evaluation for individualized patient management strategies.
In addition to stimulating new groundbreaking ideas and collaborations, this program has had extensive participation from the members of the professional and non-profit organizations playing a central role in:
- Developing clinical guidelines for patient care (e.g., National Comprehensive Cancer Network, American Urologic Association, American College of Radiology, and other organizations); and
- Creating national and global scientific strategy and related infrastructure (e.g., President Joe Biden’s Cancer Moonshot Program, National Cancer Institute/NIH, Movember Foundation).
AGPS and AdMeTech Foundation: Goal of AGPS – integration of imaging with other diagnostic tools and treatment – represents a natural evolution of the AdMeTech Foundation’s programs. Since its creation in 1997 as a non-profit 501c3 organization, AdMeTech has been leading national and international groundbreaking programs in research and medical education, public awareness and advocacy, and health equity. AdMeTech pioneered –
- Development and pilot testing of precision prostate MRI and image-guided robotics for biopsy and treatment since 1998.
- Development and evaluation of molecular imaging, with the primary focus on PSMA imaging since 2001.
- PI-RADS standardization of prostate MRI since 2010. This effort enabled multi-center clinical evaluation and large-scale implementation since 2010.
Since the inaugural AGPS in 2016, AdMeTech has been leading medical education and research in integrated precision diagnostics, including radiogenomics specifically and multiomics in general.
Based on the findings and recommendations of AGPS 2022, AdMeTech created International Working Group on Image-Guided Focal Treatment of Prostate Cancer, which has been instrumental in prioritizing development of short-term, image-based patient outcomes for expediting large-scale clinical evaluation and adoption of partial ablation (“male lumpectomy”).
Between 2024 and 2025, AdMeTech’s Working Group designed pilot studies for assessment of patients after focal treatment, with the following goals:
- To evaluate the role of molecular imaging; and
- To develop and test a broadly accepted, standardized approach to MRI intepretation (PI-MAPS, or Prostate Imaging-MRI Assessment Post-ablation Scoring System).
EXECUTIVE SUMMARY – AGPS 2025: AGPS 2025 reviewed state of the art and emerging advances in major aspects of prostate cancer care, including:
- “Smart” screening, integrating PSA testing with imaging and/or liquid biomarkers;
- Precision diagnosis and its integration with individualized management strategies for localized and advanced disease;
- Image-guided focal treatment and partial ablation, including progress report, recommendations and planned research of the AdMeTech’s Working Group; and
- The critical role of bioinformatics, artificial intelligence, machine and deep learning for clinical data integration (including multiomics) for every stage of patient care.
Similarly to the past annual events, AGPS 2025 made a significant impact on the current and future vision for precision care of prostate cancer, had extensive participation of the international key opinion leaders (KOLs), and offered high visibility of the presented novel ideas, research and innovations during and after the event. AGPS 2025’s International Organizing Council (IOC) ensured the highest global participation in this event’s history, with over 400 registrants, mostly physicians (compared to about 300 participants in 2023 and 2024).
- High Impact on the state of the art and future vision for prostate cancer care: AGPS 2025 has had a consistent and positive response to the event content from general attendees, faculty, and sponsors – regarding the quality of speakers, program and discussions.
- Participating physicians and scientists have reported that this event has made a strong impact on their clinical practice, and general strategy and novel ideas for research.
- Industry leaders have reported a direct and strong impact of this event on their short- and long-term strategy for product development, related research, positioning and large-scale clinical adoption.
- All participants reported multiple networking opportunities that played an important role in establishing new collaborations and partnerships, including those with other Summit participants.
- Cross-disciplinary clinical and scientific dialogue among academic and industry leaders and related consensus on the best emerging clinical practices and research priorities has been effectively maintained – if not enhanced – in a virtual setting.
- Expansion of partnership with Grand Rounds in Urology (GRU), resulting in the post-event online publication of scientific presentation videos and reaching over 15,000 physicians internationally.
- Since 2018, GRU’s Editor-in-Chief Dr. David Crawford was instrumental in establishing AdMeTech’s collaboration with GRU, serving as the Media Partner. After AGPS 2015, Dr. Crawford and other GRU leaders invited AdMeTech to continue this partnership. Dr. Crawford expressed his interest in ensuring “the semination of information from your meeting, which I really believe is the best in the country for prostate cancer. I am amazed how you were able to collate all the facts and future direction into one meeting”.
- Extensive participation of the KOLs of multiple clinical subspecialties: Unlike most prostate cancer meetings, our Summit brought together KOLs, representing every clinical expertise involved in prostate cancer care and serving as the key leaders of multiple academic institutions and major professional societies.
- Participation of the KOLS has been instrumental in the development and implementation of a multi-disciplinary consensus on the best clinical practices and research priorities.
- Summit 2025 had extensive representation from the committees and organizations developing the cutting-edge clinical guidelines or funding research – including, but not limited to, American College of Radiology (ACR), Radiologic Society of North America (RSNA), National Comprehensive Cancer Network (NCCN), European Association of Urology (EAU), American Urologic Association (AUA), American Society for Radiation Oncology (ASTRO), European Society for Medical Oncology (ESMO), and other organizations in radiology, urology, medical oncology, pathology, and radiation oncology
- An important opportunity to influence the influencers: Extensive exposure of presentations during the Summit. Participation of the international, multi-disciplinary KOLs has created a strong positioning of the presented innovations and related data. For all sponsors in 2025, Summit organizers have offered sponsored presentations during the main scientific program for maximum exposure.
- High rate of the faculty retention: Most Summit speakers have been participating in this annual event since the time of its establishment in 2016. They have been serving as volunteers for the Summit Governing Board, Steering Committee and International Organizing Committee.
- Increased attendance: : Over 400 attendees registered in 2025 (compared to 300 in 2024), reflecting a rapidly growing international participation of physicians. Several speakers, excited about the Summit 2023 and Summit 2024, volunteered to serve on the International Organizing Council (IOC) for Summit 2025 to bring the high-quality education offered by the Summit to their regions and countries. IOC has played the key role in expanding global physicians’ participation, particularly from the Middle East, Africa, Eastern and Central Europe, Central and South America, and Asia, in addition to the previous actively participating regions (US, Canada, Western Europe, and Australia).
- Summit 2025, similarly to the past annual events, had the following hallmarks:
- Stimulating cross-disciplinary consensus on the best emerging clinical practices and research priorities; and
- Expediting and ensuring connection between the key opinion leaders and sponsors (via break-out rooms or personal email introductions)..
- High visibility of presentations after the Summit: The large majority (over 95%) of the presentations (including sponsored talks) were published online in a video format by Grand Rounds in Urology (GRU) within several weeks after the Summit. AdMeTech and GRU dedicated newsletters – highlighting individual talks – ensure a joint outreach to over 21,000 physicians. GRU leadership and staff pointed out consistently since 2019 that the published Summit presentations have had a high viewing rate; and
PLANS FOR AGPS 2026:
Summit 2026 will address a full spectrum of patient care strategies:
- Current and future advances in screening and clinical evaluation of men prior to diagnosis of prostate cancer (PC)
- Selection of patients for biopsies and improved tissue sampling
- Improved diagnosis of localized PC and selection of patients for appropriate care (e.g., active surveillance, image-targeted partial ablation, or immediate whole-gland treatment, such as radical surgery or radiation)
- Improved diagnosis and treatment of recurrent and advanced PC, including oligometastatic and systemic metastatic disease
- Expanded discussion on the priority research needs in image-guided, minimally-invasive treatment and emerging data on its clinical utility compared to other clinical interventions
- Increased participation of the organizations leading training, accreditation, regulatory and reimbursement policies to expedite clinical evaluation and adoption of promising novel diagnostics and therapeutics
- Role of precision care in reducing health disparities; and
- Discussion of the emerging role of bioinformatics, artificial intelligence, machine and deep learning for management and implementation of integrated multi-modality diagnostics for predictive and prognostic modeling.
FOR MORE INFORMATION: To learn more about the background and history of AGPS in general, AGPS 2025, and plans for AGPS 2026, please visit here.